Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
about
Meta-STEPP: subpopulation treatment effect pattern plot for individual patient data meta-analysis.Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.From concepts, theory, and evidence of heterogeneity of treatment effects to methodological approaches: a primerMeasuring the performance of markers for guiding treatment decisionsImproving Patient Care Using the Johnson-Neyman Analysis of Heterogeneity of Treatment Effects According to Individuals' Baseline CharacteristicsStrategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.Clinical trials in the era of personalized oncology.Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding TreatmentPredicting benefit of endocrine therapy for early breast cancerPatterns and risk factors for locoregional failures after mastectomy for breast cancer: an International Breast Cancer Study Group reportObesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer.HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerAbsolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.Subpopulation Treatment Effect Pattern Plot (STEPP) analysis for continuous, binary, and count outcomes.A visualization method measuring the performance of biomarkers for guiding treatment decisions.Treatment selection in a randomized clinical trial via covariate-specific treatment effect curves.A multivariable model to guide the decision for pessary placement to prevent preterm birth in women with a multiple pregnancy: a secondary analysis of the ProTWIN trial.Identifying treatment effect heterogeneity in clinical trials using subpopulations of events: STEPPExploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.Evaluation of biomarkers for treatment selection using individual participant data from multiple clinical trials.Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
P2860
Q31075630-B11EA7F8-134F-43B8-ACCA-9215ACE2F3E0Q33766404-746A1925-6966-43B5-BBB3-2CDE5C9D4704Q34509675-C9D7792A-AA85-44B3-BE17-1A09482A1AE9Q34897226-42A652FA-1CAA-4AB2-A238-0A9B57243AD7Q35105710-93E66F06-1CF8-4CF7-94C2-64E226675856Q35130819-48624FAD-19C6-4559-977E-D9397493338DQ35230269-69542224-76FC-4193-A40F-AAEC2DB88AF9Q35230273-D8815A57-DE91-450C-ADAA-F21D4F327540Q35450768-FEB0CE64-BA6D-4DAE-83D0-78449E912254Q35555963-A3CC0EF3-8FCE-40B6-992B-CFB667E1DD89Q35557992-A830ABDF-A914-4959-81B2-4AA4B3B0D159Q35607675-18AC1CDD-4C47-4261-94FB-0CC669DFB2C8Q36173510-F2F5E6D1-01BC-4AF6-8E07-D5F29E08C7F4Q36271534-7032DC31-3830-408D-BA74-87833F61FDECQ36337766-3C2AACD8-876E-474E-BC9E-108C3EFF9DA5Q36368902-077A802A-1B0B-4B26-BAB3-A2288AF60984Q36494245-7C0DC89D-C54E-4BD2-9BC8-1B3A007E2C5FQ36568213-8364505D-2E63-468F-89F2-8202C94FCA69Q36713321-F3B338EE-5625-434F-857B-9F29164FD8E8Q36715181-8240429A-585E-4A00-9970-FAB8DE8F6BB4Q36903047-178FE8BF-446F-40D2-BCC8-A1402CE98752Q37130142-7775D8BB-9C5C-410F-A3B8-B0C49D088DE8Q37160109-CD4F475B-BFE6-4774-B40B-CDEC33076614Q38380910-B1D136BC-25B9-49E0-B1DE-A7138A4DFCCCQ38935953-55D788C0-278A-4D6C-B915-0D1E1E5A8F84Q39164342-A9077223-4CB1-4940-8474-5679010C9E9EQ40126025-3FD2AFE9-5D61-4DE2-96E1-FB90255B1917Q40402182-158C1417-453D-4029-A2BC-1805C98C50E5Q43841288-5DBC7EC5-0A0F-4C3E-B135-233940B7EBC3Q49996939-3137F9DC-94E6-4E2C-9119-D437DB30E90DQ51142261-8110061B-0D3D-4879-B61C-125717802F95Q54376091-602639D0-2BCA-4625-9115-972486B3E985
P2860
Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluation of treatment-effect ...... treatment effect pattern plot.
@ast
Evaluation of treatment-effect ...... treatment effect pattern plot.
@en
Evaluation of treatment-effect ...... treatment effect pattern plot.
@nl
type
label
Evaluation of treatment-effect ...... treatment effect pattern plot.
@ast
Evaluation of treatment-effect ...... treatment effect pattern plot.
@en
Evaluation of treatment-effect ...... treatment effect pattern plot.
@nl
prefLabel
Evaluation of treatment-effect ...... treatment effect pattern plot.
@ast
Evaluation of treatment-effect ...... treatment effect pattern plot.
@en
Evaluation of treatment-effect ...... treatment effect pattern plot.
@nl
P2093
P2860
P356
P1476
Evaluation of treatment-effect ...... treatment effect pattern plot
@en
P2093
Ann A Lazar
Bernard F Cole
Richard D Gelber
P2860
P304
P356
10.1200/JCO.2009.27.9182
P407
P577
2010-09-13T00:00:00Z